Navigation Links
GeneGo Is Awarded NCI Grant for Development of Systems Biology Database and Tools for Nutrition in Cancer in Collaboration with the FDA
Date:9/30/2008

ST. JOSEPH, Mich., Sept. 30 /PRNewswire/ -- GeneGo Inc., a leading provider of databases, tools and services in systems biology, announced today that they were awarded with a Phase I SBIR grant from the National Cancer Institute (NCI) for the development of a platform for understanding the influence of nutrients on cancerogenesis and cancer prevention. GeneGo will collaborate with FDA investigator, Jim Kaput Director of Personalized Nutrition and Medicine, on the project. The new platform will include a comprehensive manually curated database on nutrition, an OMICs data repository, advanced search and statistical modeling tools.

"For the last 60 years, it has been well established that cancer and nutrition are intrinsically connected," said Yuri Nikolsky, CEO of GeneGo and the grant's PI. "However, this knowledge is scattered in thousands of sources, which are difficult to annotate and categorize. We will assemble the first specialized database on the topic and develop automated tools for data analysis. The new platform will be primarily targeting healthcare professionals and nutritionists."

About GeneGo, Inc.

GeneGo, Inc. develops systems biology technology such as compound based pathway analysis, cheminformatics & bioinformatics software for life science research. The original computational MetaDiscovery(TM) platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 5.0(TM), assists pharmaceutical scientists in the areas of target selection and validation, data mining in biology, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 5.0(TM) is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase(TM) represents the knowledge base for MetaCore.

For more information, please visit the company's web site at http://www.genego.com.


'/>"/>
SOURCE GeneGo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. GeneGo and the Cystic Fibrosis Foundation Collaborate to Advance Understanding of Cystic Fibrosis
2. GeneGo Enters Multi-Year Agreement With Bristol Myers Squibb for Access to GeneGo Software Suite and Databases
3. Utrecht University Licenses MetaDrug From GeneGo for Drug Innovation
4. GeneGo Integrates With Cytoscape
5. UC Berkeley Expands Molecular Toxicology Curriculum to Include GeneGos Platform
6. GSK Extends GeneGo License and Adds New Products
7. GeneGo Collaborates With The Netherlands Toxicogenomics Center on $100 Million Grant
8. VTT Technical Research Centre of Finland Licenses MetaCore from GeneGo for Cancer Research and Diagnostics
9. Unilever Extends Their GeneGo MetaCore License
10. Yale Keck Microarray Center Becomes a GeneGo Center of Excellence
11. University of Miami Miller School of Medicine Becomes a GeneGo Center of Excellence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... NC (PRWEB) , ... June 27, 2016 , ... ... mission to bring innovative medical technologies, services and solutions to the healthcare market. ... and implementation of various distribution, manufacturing, sales and marketing strategies that are necessary ...
(Date:6/24/2016)... June 24, 2016 Epic Sciences unveiled ... cancers susceptible to PARP inhibitors by targeting homologous ... (CTCs). The new test has already been incorporated ... multiple cancer types. Over 230 clinical ... response pathways, including PARP, ATM, ATR, DNA-PK and ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
(Date:6/23/2016)... 23, 2016  The Prostate Cancer Foundation (PCF) is pleased to ... faster cures for prostate cancer. Members of the Class of 2016 were selected ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology:
(Date:6/21/2016)... , June 21, 2016 NuData ... the new role of principal product architect and ... the director of customer development. Both will report ... technical officer. The moves reflect NuData,s strategic growth ... response to high customer demand and customer focus ...
(Date:6/9/2016)... 9, 2016  Perkotek an innovation leader in attendance control systems is proud to ... hours, for employers to make sure the right employees are actually signing in, and ... ... ... ...
(Date:6/2/2016)... 2, 2016 The Department of Transport ... the 44 million US Dollar project, for the , ... including Personalization, Enrolment, and IT Infrastructure , to ... production and implementation of Identity Management Solutions. Numerous renowned international ... Decatur was selected for the most compliant ...
Breaking Biology News(10 mins):